Deciphera (DCPH) Q4 Loss Narrower Than Expected, Revenues Beat [Yahoo! Finance]
Deciphera Pharmaceuticals, Inc. (DCPH)
Last deciphera pharmaceuticals, inc. earnings: 3/9 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
deciphera.com/investor-relations
Company Research
Source: Yahoo! Finance
In the year-ago quarter, DCPH had incurred a loss of 60 cents per share. Net revenues were $48.3 million, which beat the Zacks Consensus Estimate of $46 million. The figure rose almost 33% year over year. Quarter in Detail Total revenues comprise net product and collaboration revenues for Qinlock (ripretinib). Deciphera's sole marketed drug, Qinlock, was approved by the FDA in 2020 to treat adult patients with advanced gastrointestinal stromal tumors (GIST), who received prior treatment with three or more kinase inhibitors, including Novartis' Gleevec (imatinib). Qinlock was approved in Europe in late 2021. Apart from Qinlock, there is no marketed drug in the company's portfolio. Net product revenues from Qinlock sales were $46.7 million, up 41.9% year over year. The drug generated sales of $35.3 million and $11.4 million in the United States and ex-U.S. markets, respectively. Qinlock's net product revenues beat the Zacks Consensus Estimate of $44.7 million and our model e
Show less
Read more
Impact Snapshot
Event Time:
DCPH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DCPH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DCPH alerts
High impacting Deciphera Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
DCPH
News
- Lifshitz Law PLLC Announces Investigations of DCPH, SLCA, HCP, and HTLFAccesswire
- SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MCBC, DCPH, HTLF, TBNKPR Newswire
- Biotech Stock Roundup: GILD's GSK' Q1 Earnings, DCPH Soars on Acquisition News & More [Yahoo! Finance]Yahoo! Finance
- DECIPHERA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Deciphera Pharmaceuticals, Inc. - DCPHBusiness Wire
- Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) was downgraded by analysts at Leerink Partnrs from an "outperform" rating to a "market perform" rating.MarketBeat
DCPH
Earnings
- 2/6/24 - Beat
DCPH
Sec Filings
- 4/30/24 - Form SC
- 4/30/24 - Form SC14D9C
- 4/29/24 - Form SC14D9C
- DCPH's page on the SEC website